|
Total
|
UC
|
PUC
|
MPC
|
P-Value*
|
---|
Age
| | | | |
0.057**
|
Range
|
29-75
|
29-75
|
46-70
|
56-70
| |
Mean
|
60.9
|
61.0
|
57.9
|
62.3
| |
Median
|
61.7
|
61.9
|
59.3
|
60.8
| |
Gender
|
205
|
178
|
18
|
9
|
0.116
|
Female
|
45 (22%)
|
43 (24%)
|
2 (11%)
|
0 (0%)
| |
Male
|
160 (78%)
|
135 (76%)
|
16 (89%)
|
9 (100%)
| |
pT
|
205
|
178
|
18
|
9
|
0.168
|
pT1
|
5 (2,5%)
|
5 (3%)
|
0 (%)
|
0 (0%)
| |
pT2
|
22 (11%)
|
19 (11%)
|
3 (17%)
|
0 (0%)
| |
pT3
|
142 (69%)
|
125 (70%)
|
13 (72%)
|
4 (45%)
| |
pT4
|
36 (17.5%)
|
29 (16%)
|
2 (11%)
|
5 (55%)
| |
Grade (1973)
|
205
|
178
|
18
|
9
|
0.263
|
Grade 2
|
22 (11%)
|
22 (12%)
|
0 (0%)
|
0 (0%)
| |
Grade 3
|
183 (89%)
|
156 (88%)
|
18 (100%)
|
9 (100%)
| |
Grade (2004)
| | | | | |
Low-grade
|
0%
|
0%
|
0%
|
0%
| |
High-grade
|
100%
|
100%
|
100%
|
100%
| |
pN
|
205
|
178
|
18
|
9
|
0.743
|
pN0
|
90 (44%)
|
80 (45%)
|
6 (33%)
|
4 (44.4%)
| |
pN1
|
45 (22%)
|
40 (22.5%)
|
3 (17%)
|
2 (22.2%)
| |
pN2
|
69 (33.5%)
|
57 (32%)
|
9 (50%)
|
3 (33.3%)
| |
pN3
|
1 (0.5%)
|
1 (0.5%)
|
0 (0%)
|
0 (0%)
| |
pM
|
205
|
178
|
18
|
9
|
1.000
|
pM0
|
204 (99.5%)
|
177
|
18 (100%)
|
9 (100%)
| |
pM1
|
1 (0.5%)
|
1
|
0 (0%)
|
0 (0%)
| |
Chemotherapy
|
205
|
178
|
18
|
9
|
0.043
|
Gc
|
39
|
39 (%)
|
0 (0%)
|
0 (0%)
| |
M-vec
|
80
|
64 (%)
|
11 (61%)
|
5 (55%)
| |
Cm
|
86
|
75 (%)
|
7 (39%)
|
4 (45%)
| |
Survival
|
205
|
178
|
18
|
9
|
0.061
|
Alive
|
120
|
109
|
6 (33.3%)
|
5 (55%)
| |
Dead
|
85
|
69
|
12 (66.6%)
|
4 (45%)
| |
- Abbreviations: Gc - Gemcitabine, cisplatin, M-vec - Methotrexate, vinblastine, epirubicin and cisplatin, Cm – Cisplatin, methotrexate.
- * statistical test: Fisher’s exact test.
- ** statistical test: t-test.